“尼古丁概念股”实控人连续减持，或再套现1.2亿

Core Viewpoint - The company Zhuhai Rundu Pharmaceutical Co., Ltd. is experiencing significant shareholder activity, with major shareholder Li Xi planning to reduce his stake by approximately 10.05 million shares, following a previous reduction that generated over 87 million yuan in cash [1][2]. Group 1: Shareholder Activity - Li Xi intends to reduce his holdings by up to 10,046,797 shares, representing 3.00% of the company's total share capital, between January 8, 2026, and April 7, 2026 [1]. - In the previous month, Li Xi successfully reduced his holdings by approximately 6.82 million shares, resulting in cash proceeds of about 87.98 million yuan [2]. Group 2: Company Performance - The company has faced declining performance, with 2024 revenues of 1.18 billion yuan, a year-on-year decrease of 8.48%, and a net profit of 39.88 million yuan, down 40.38% [3]. - In the first half of 2025, revenues were approximately 548.06 million yuan, also down 8.22%, with a net loss of about 36.19 million yuan [3]. Group 3: Business Operations - Rundu Pharmaceutical's main business includes chemical drug formulations and raw materials, with a focus on cardiovascular, anti-infection, digestive, and analgesic treatments [2]. - The company’s subsidiary, Rundu Jingmen, has been recognized for its nicotine raw material production, although this segment has not yet significantly impacted overall company performance [4]. - The subsidiary has received regulatory approvals and has seen an increase in production capacity, with a focus on new tobacco products [4]. Group 4: Market Position - Rundu Pharmaceutical is considered a "nicotine concept stock" in the A-share market, but the nicotine-related business has not yet provided a substantial boost to the company's financial performance [2][4]. - The number of shareholders in Rundu Pharmaceutical has decreased for 11 consecutive periods, with a total reduction of 40.50%, indicating a concentration of shares [4].